Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Hanze University of Applied Sciences Groningen | OTHER |
Not provided
Not provided
Not provided
The goal of this study is to determine whether intervention by the PRIME clinic influences cardiac treatment decisions, as well as patients quality of life and healthcare utilization.
The main questions this study aims to answer are:
Participants will:
The primary outcome of this study is the difference between treatment recommendations; the first treatment recommendation (the decision before the patient visits the outpatient clinic) will be compared with the treatment recommendation after the assessment at the outpatient clinic.
Secondary and other outcomes that will be collected are baseline demographic data including age, gender, body mass index, education level, European System for Cardiac Operative Risk Evaluation II (EuroSCORE II) and co-morbidities such as stroke, reduced cognitive function, chronic obstructive pulmonary disease (COPD) GOLD III or IV, renal failure (a reduced renal function prior to surgery with a kreatinine level ≥150mmol/L), a reduced left ventricular function, reduced mobility, cardiac reoperation and type of surgical procedure (CABG, valve replacement or repair, surgery of the thoracic aorta or a combination of several procedures).
Data will be collected using several questionnaires:
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| PRIME-Group | Experimental |
| |
| Control Group | No Intervention |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Geriatric assessment | Diagnostic Test | At the clinic further information on the somatic, social, psychological and functional domain will be gathered by the nurse and two validated tests to map the vulnerability and resilience of the patient will be used; the Cognitive Impairment Test and the timed Up and Go Test. |
| Measure | Description | Time Frame |
|---|---|---|
| The difference between the treatment recommendation provided by the multidisciplinary Heart Team prior to the patients visit to the PRIME-clinic and the treatment advice from the Heart Team after the patients visit to the PRIME-clinic. | After the patient is referred to the UMCG, the patients situation is discussed by the heart team, resulting in a treatment recommendation, which is documented in the electronic patient record. If the patient meets the inclusion criteria for the PRIME-study, they will also be invited to the PRIME-clinic (usually within a week). The findings from the PRIME-clinic are then discussed the same day during the heart team meeting, after which a treatment recommendation is formulated again. A difference in treatment recommendation is noted when the initial recommendation is revised, opting for a less invasive or conservative treatment instead of open-heart surgery. | From enrollment to the second treatment advice of the heart team, typically within 8 weeks. . |
| Measure | Description | Time Frame |
|---|---|---|
| Health related quality of life, SF-36 | Health-related quality of life is measured using the validated SF-36 questionnaire, which consists of 36 items that assess eight health dimensions: physical functioning, role limitations due to physical health issues, role limitations due to emotional problems, social functioning, emotional well-being, energy levels and fatigue, pain, and overall perceptions of general health. Each domain is scored on a scale from 0 to 100, with higher scores indicating better health. Two composite scores can be derived from these domains: the Physical Component Score and the Mental Component Score. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| dr. Fredrike Zwiers-Blokzijl | Contact | +31 50 361 56 17 | f.zwiers-blokzijl@umcg.nl | |
| Milou S.H. van Dieen | Contact | m.s.h.van.dieen@umcg.nl |
| Name | Affiliation | Role |
|---|---|---|
| Prof. dr. Mariani | University Medical Center Groningen | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University Medical Center Groningen | Recruiting | Groningen | Provincie Groningen | Hanzeplein 1 9713 GZ Groningen | Netherlands |
We will make the dataset available once all data has been anonymized.
The protocol will be made available after it has been published.
The data will be available on reasonable request.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Shared decision-making conversation | Other | The nurse and nurse practitioner together will talk with the patient and their partner about possible treatment options as well as patients' expectations, preferences and their life in general. During the conversation the OPT (Outcome Prioritization Tool) will be used to clarify the most important goals of treatment for the patient. The OPT exists of four universal treatment goals rated on a visual analogue scale from 0 to 100. The goals represented are: life extension, maintaining independence, reducing pain and reducing other symptoms. The goals will be explained and the patient will be asked to rate each outcome according to the trade-off principle meaning that two outcomes cannot be rated equally. |
|
| From enrollment to one year after |
| The cost-effectiveness ratio, an analysis that combines both the EQ-5D-5L (for health gains) and the Medical Cost Questionnaire (for costs) | Both the MCQ and EQ-5D-5L will be administered at 3, 6, 9, and 12 months following the PRIME-clinic visit. The MCQ will be used to measure the healthcare utilization. This includes both direct medical costs (such as hospitalizations, medication, and treatments) as well as indirect costs (such as productivity losses). Additionally, Quality-Adjusted Life Years (QALYs) are calculated using the EQ-5D-5L, which measures health-related quality of life. Using these data (QALYs and costs), the cost per QALY is calculated, representing the ratio between the costs of treatment and the health gains achieved. A lower cost per QALY indicates that the treatment is more cost-effective. | From enrollment to one year after |
| ID | Term |
|---|---|
| D000073496 | Frailty |
| ID | Term |
|---|---|
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided